Science 37® extends its leadership – GuruFocus.com

RESEARCH TRIANGLE PARK, NC, May 10, 2022 (GLOBE NEWSWIRE) — Science 37 Holdings, Inc. (SNCE), the Agile Clinical Trial Operating System™, today introduced a landmark technology release, setting the bar as the most comprehensive and comprehensive end-to-end platform to fully orchestrate the conduct of studies for decentralized clinical trials (DCTs) and increasingly agile designs that require remote and onsite management.

Rising demand for decentralized and agile clinical research delivery models has forced sponsors and CROs to implement numerous point-solution technologies, often resulting in disconnected processes that lead to study delays and threaten quality Datas. Unlike many point solutions that allow for decentralization components, the Science 37 technology platform offers the most comprehensive end-to-end solution in the industry.

Purpose-built to fully orchestrate the conduct of studies among all clinical trial stakeholders, Science 37’s platform coordinates and unifies the stakeholder journey at every clinical trial visit, with exceptional data capture capabilities to increase compliance and generate the highest quality data.

Science 37 has bolstered its SaaS platform with advanced configuration features for visit plans and forms with its latest release. The enhanced platform includes an eCOA library, with assessments pre-approved by licensees, and enables automation of the translation process to accelerate global study deployment. Technology platform features are available as full service, self-service (SaaS), or self-service with Science 37 support.

“There is a fundamental shift towards decentralization, and the industry needs a proven integrated solution,” said David Coman, Science 37’s chief executive. “Our new version of the platform delivers that and more. , with a front-end that unifies all stakeholder journeys, improves compliance, and drives high-fidelity data, paired with a back-end that delivers speed, flexibility, and scalability.

The new version of the Science 37 platform was developed in collaboration with beta customers including Boehringer Ingelheim and Thermo Fisher Scientific.

“Boehringer Ingelheim believes in the value of agile clinical trials to develop innovative medicines for patients faster,” said Uli Broedl, senior vice president, head of global clinical development and operations at Boehringer Ingelheim. “We are excited about our collaboration with Science 37 to develop this highly innovative platform and look forward to leveraging its capabilities in our efforts to advance patient-centric clinical development.”

“Our long-standing partnership with Science 37 has allowed Thermo Fisher Scientific to help set the direction for the new technology release of Science 37,” said David M. Johnston, Ph.D., senior vice president and President, Clinical Research, Thermo Fisher Scientific . “We are looking to leverage Science 37’s new platform to build and deploy digital solutions ranging from eCOA to fully decentralized clinical trials.”

“With the proliferation of decentralization and the increased use of digital technologies, sponsors are facing new challenges with the integration of various piecemeal solutions,” said Dr. Nimita Limaye, Vice President of Research , Life Sciences R&D Strategy and Technology, IDC. “The industry needs a purpose-built technology platform to help streamline the user experience across all care settings, ensure better compliance and accelerate study construction. The latest version of the Science 37 platform helps strengthen these capabilities and accelerate study times.

To learn more about the Science 37 technology platform, visit www.science37.com/technology.

About Science 37
The mission of Science 37 Holdings, Inc. (SNCE) is to enable universal access to clinical research, facilitating the participation of patients and providers from anywhere and helping to accelerate the development of treatments that have an impact. on the lives of patients. As a pioneer in decentralized clinical trials, the Science 37l operating system (OS) supports today’s more agile clinical research designs with its comprehensive, end-to-end technology platform and networks centralized patient communities, telemedicine interviewers, mobile nurses, coordinators, provider communities, data and devices. Configurable to enable nearly any type of study, the Science 37 operating system enables up to 15x faster recruitment, 28% better retention, and a 3x more diverse patient population with workflow orchestration. industry-leading work, evidence generation and data harmonization. For more information, visit https://www.science37.com.

MEDIA INQUIRIES:

Drew Bustos
Science 37
[email protected]

INVESTOR RELATIONS:

Caroline-Paul
Gilmartin Group
[email protected]

Science-37-Inc-.png

Comments are closed.